What went wrong at CVS?
Pharmacy chains are in crisis
The pharmacy industry is in crisis. That's especially true at CVS, where layoffs are piling on top of layoffs — and the future of the company is in question.
CVS Health announced this month that it is laying off 2,000 workers, CNN said, as part of an effort to "slash costs" across the company. That's on top of the 5,000 layoffs it announced last year, and after the company closed around 900 stores in recent years. CVS and other drug store chains are "struggling" due to falling reimbursement rates for prescription drugs, CNN said. "Our industry faces continued disruption, regulatory pressures and evolving consumer needs and expectations," said a company spokesperson.
What did the commentators say?
CVS' problems are also "very specific to the company," said Axios. In addition to its pharmacies, CVS is also a "major insurer" — it bought Aetna in 2017 — as well as a pharmacy benefit manager. Yes, "retail pharmacy in general is struggling," but CVS' challenges "could just be the specific businesses it has combined," Axios said. That's why company leaders are reportedly considering breaking up those businesses — an extraordinary move in an era where "vertical integration is all the rage."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"Satisfaction with brick-and-mortar pharmacies dropped 10 points in 2024," said Time. Customers report short-staffed outlets with "long lines and frustrating experiences." It's not just CVS: Rite Aid recently emerged from bankruptcy, and Walgreens is planning to close one-fourth of its roughly 8,600 stores. Customers simply didn't return to brick-and-mortar stores after the pandemic, preferring cheaper online alternatives. "The current pharmacy model is not sustainable," Walgreens CEO Tim Wentworth said in June.
That affects communities. The mass closure of retail pharmacies is a "growing worry for health experts," said the Missouri Independent. The problem is "most acute" in places with low incomes — "urban cores" and rural areas where pharmacies are the "convenience stores of the health care system." That makes getting necessary medications a growing challenge for the people who live in those places. "When those community pharmacies close, communities lose critical access," said one expert.
One other factor in the struggles of CVS and its industry: "Heavy competition" from Amazon and Walmart, said the Los Angeles Times. Pharmacy benefit managers (PBMs) also play a role — they have "significant control" over how much insurers pay pharmacies for medications and have worked to push down those reimbursement costs. That pushes down pharmacy profitability. One irony: CVS owns Caremark, a PBM. "That's made the drug retail business more healthy," said one analyst — but it still hasn't made CVS "immune to market forces," said the Times.
What next?
CVS' board is looking at "splitting the company," said The Wall Street Journal. That could be difficult. The spun-off businesses "might struggle to flourish on their own." The mergers with Aetna and Caremark were supposed to "bring down costs and give patients more convenient, accessible care." That didn't pan out. Now the future of the company is in limbo, the Journal said: CVS' board "isn't expected to make a decision soon."
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Joel Mathis is a writer with 30 years of newspaper and online journalism experience. His work also regularly appears in National Geographic and The Kansas City Star. His awards include best online commentary at the Online News Association and (twice) at the City and Regional Magazine Association.
-
Russia's best investment
Opinion Eric Adams isn't the only politician with foreign benefactors
By William Falk Published
-
6 show-stopping homes with striking interiors
Feature Featuring a copper tree entry in Oregon and a home inspired by a Japanese hunting lodge in California
By The Week Staff Published
-
'In short, the good economic news is real'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
The 'game-changing' treatment for schizophrenia
The Explainer US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects
By Harriet Marsden, The Week UK Published
-
The audio industry is working to tackle hearing aid stigma
The Explainer Only 1 in 5 people who could benefit from hearing aids use them, according to the Hearing Loss Association of America
By Justin Klawans, The Week US Published
-
Mold, bugs at listeria-linked Boar's Head meat plant
Speed Read Food safety inspectors reported many violations at a Virginia plant that has been linked to a nationwide deli meat recall
By Peter Weber, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
The battle for abortion buffer zones
The Explainer A 2023 law banning protests around clinics remains unenforced amid dispute over 'silent prayer'
By Harriet Marsden, The Week UK Published
-
WHO declares mpox a global health emergency
Speed Read An outbreak of the viral disease formerly known as monkeypox continues to spread in Africa
By Rafi Schwartz, The Week US Published
-
Why gonorrhoea is becoming 'untreatable'
In the Spotlight Infections hit record high as experts warn about rise in antibiotic-resistant cases
By Elizabeth Carr-Ellis, The Week UK Published
-
Where does MDMA-assisted therapy go from here?
Today's Big Question Psychedelic treatments face a challenge from the FDA
By Joel Mathis, The Week US Published